Glioblastoma multiforme (GBM) is one of the most lethal malignant solid tumors, with a very low 5-year survival rate. Despite considerable number of achievements in neurosurgery, radiotherapy and chemotherapy, little progress has been made in prolonging the survival of GBM. The recognition of the two prognostic biomarkers, isocitrate dehydrogenase (IDH) and O6-methylguanine-methyltransferase (MGMT) largely promoted the development of non-invasive biomarkers for accurate and early diagnosis of the disease, as well as a strategy to improve the treatment of GBM patients. Biomarkers can be used as drug targets to develop therapies in the hope of ultimately defeating GBM. Discovering new factors is indeed a very arduous journey, but with advances in genomics and proteomics research, more and more factors have been discovered and tested to regulate various phenotypes of GBM. Thus, not only the search for new efficient factors of GBM is significant, but also improved understanding by studying at the complex molecular pathways of the disease.
This Research Topic aims at presenting the trending and recent advances in effective therapy for GBM with classical molecular factors of GBM. And it also aims at presenting newly discovered molecules on disease progression, therapeutic target and radiation therapy resistance of GBM.
We welcome the submissions of Review, Mini-Review and Original Research articles covering, but not limited to, the following subtopics:
• Discovery of new molecules which have significance on early diagnosis and effective therapy of GBM
• Elucidation of the mechanism of molecules in the pathogenesis and potential cure of GBM
• Development of targeted drugs based on specific biomarkers of GBM
• Development of strategies with gene therapy and immunotherapy based on specific biomarkers of GBM
• Design of drug delivery systems for GBM treatment based on specific biomarkers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Glioblastoma multiforme (GBM) is one of the most lethal malignant solid tumors, with a very low 5-year survival rate. Despite considerable number of achievements in neurosurgery, radiotherapy and chemotherapy, little progress has been made in prolonging the survival of GBM. The recognition of the two prognostic biomarkers, isocitrate dehydrogenase (IDH) and O6-methylguanine-methyltransferase (MGMT) largely promoted the development of non-invasive biomarkers for accurate and early diagnosis of the disease, as well as a strategy to improve the treatment of GBM patients. Biomarkers can be used as drug targets to develop therapies in the hope of ultimately defeating GBM. Discovering new factors is indeed a very arduous journey, but with advances in genomics and proteomics research, more and more factors have been discovered and tested to regulate various phenotypes of GBM. Thus, not only the search for new efficient factors of GBM is significant, but also improved understanding by studying at the complex molecular pathways of the disease.
This Research Topic aims at presenting the trending and recent advances in effective therapy for GBM with classical molecular factors of GBM. And it also aims at presenting newly discovered molecules on disease progression, therapeutic target and radiation therapy resistance of GBM.
We welcome the submissions of Review, Mini-Review and Original Research articles covering, but not limited to, the following subtopics:
• Discovery of new molecules which have significance on early diagnosis and effective therapy of GBM
• Elucidation of the mechanism of molecules in the pathogenesis and potential cure of GBM
• Development of targeted drugs based on specific biomarkers of GBM
• Development of strategies with gene therapy and immunotherapy based on specific biomarkers of GBM
• Design of drug delivery systems for GBM treatment based on specific biomarkers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
